Longitudinal early epigenomic signatures inform molecular paths of therapy response and remission in depressed patients

Evelien Van Assche; Christa Hohoff; Johannes Zang; Matthew J Knight; Bernhard T Baune

doi:10.3389/fnmol.2023.1223216

Longitudinal early epigenomic signatures inform molecular paths of therapy response and remission in depressed patients

Front Mol Neurosci. 2023 Aug 18:16:1223216. doi: 10.3389/fnmol.2023.1223216. eCollection 2023.

Authors

Evelien Van Assche¹, Christa Hohoff¹, Johannes Zang¹, Matthew J Knight², Bernhard T Baune^{1

3

4}

Affiliations

¹ Department of Psychiatry, University of Münster, Münster, Germany.
² Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
³ Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia.
⁴ The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.

Abstract

Introduction: The etiology of major depressive disorder (MDD) involves the interaction between genes and environment, including treatment. Early molecular signatures for treatment response and remission are relevant in a context of personalized medicine and stratification and reduce the time-to-decision. Therefore, we focused the analyses on patients that responded or remitted following a cognitive intervention of 8 weeks.

Methods: We used data from a randomized controlled trial (RCT) with MDD patients (N = 112) receiving a cognitive intervention. At baseline and 8 weeks, blood for DNA methylation (Illumina Infinium MethylationEPIC 850k BeadChip) was collected, as well as MADRS. First, responders (N = 24; MADRS-reduction of at least 50%) were compared with non-responders (N = 60). Then, we performed longitudinal within-individual analyses, for response (N = 21) and for remission (N = 18; MADRS smaller or equal to 9 and higher than 9 at baseline), respectively, as well as patients with no change in MADRS over time. At 8 weeks the sample comprised 84 individuals; 73 patients had DNA methylation for both time-points. The RnBeads package (R) was used for data cleaning, quality control, and differential DNA-methylation (limma). The within-individual paired longitudinal analysis was performed using Welch's t-test. Subsequently gene-ontology (GO) pathway analyses were performed.

Results: No CpG was genome-wide significant CpG (p < 5 × 10^-8). The most significant CpG in the differential methylation analysis comparing response versus non-response was in the IQSEC1 gene (cg01601845; p = 1.53 × 10^-6), linked to neurotransmission. The most significant GO-terms were linked to telomeres. The longitudinal response analysis returned 67 GO pathways with a p < 0.05. Two of the three most significant pathways were linked to sodium transport. The analysis for remission returned 46 GO terms with a p-value smaller than 0.05 with pathways linked to phosphatase regulation and synaptic functioning. The analysis with stable patients returned mainly GO-terms linked to basic cellular processes.

Discussion: Our result suggest that DNA methylation can be suitable to capture early signs of treatment response and remission following a cognitive intervention in depression. Despite not being genome-wide significant, the CpG locations and GO-terms returned by our analysis comparing patients with and without cognitive impairment, are in line with prior knowledge on pathways and genes relevant for depression treatment and cognition. Our analysis provides new hypotheses for the understanding of how treatment for depression can act through DNA methylation and induce response and remission.

Keywords: DNA methylation; major depressive disorder; pathways; pharmaco-epigenomics; psychotherapy.